Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Profound Medical Corp.NASDAQ: PROF
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$2.24M, compared with $1.09M a year earlier. Trailing-twelve-month accounts receivables was -$3.49M. Over 3 fiscal years it compounded at -50.3% a year.
Context
- Accounts receivables amounted to 1.1% of revenue in FY2025, down 0.8 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$2.24M or moves back toward the trailing-twelve-month quarterly average of -$873.46K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (175.01K) USD
- Year-over-year change
- -194.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (175.01K) | -194.1% |
| FY2024 | 2024-12-31 | 186K | +119.5% |
| FY2023 | 2023-12-31 | (956K) | +32.9% |
| FY2022 | 2022-12-31 | (1.42M) | -171.3% |
| FY2021 | 2021-12-31 | 2M | — |
Accounts Receivables vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's LTM Mar 2026 accounts receivables of $3.49M is the 2nd largest of the 11 companies compared; the peer median is $11.5K.
- Its year-over-year change of -927.9% is the lowest of 9, against a peer median of +86.0%.
- Accounts receivables amounts to 18.5% of revenue for PROF, versus a peer median of 3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.18M | +294.6% | — | 4.7% | |
| LTM Mar 2026 | $3.49M | -927.9% | -50.3% | 18.5% | |
| LTM Mar 2026 | $3.32M | -36.0% | +8.9% | 3.1% | |
| LTM Mar 2026 | $2.39M | +188.7% | — | 4.1% | |
| LTM Mar 2026 | $1.24M | +70.4% | — | 3.9% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.13M | +23.8% | -1.2% | 61.1% |
| LTM Mar 2026 | $440K | -119.2% | — | 71.2% | |
| LTM Dec 2025 | $113.84K | +135.5% | +13.1% | 0.9% | |
| LTM Mar 2026 | $74K | — | — | 0.1% | |
| LTM Mar 2026 | $23K | +101.7% | +101.4% | 0.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding PROF) | $11.5K | +86.0% | +11.0% | 3.5% | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.7M) | (28.67M) | (28.32M) | (27.82M) | (42.57M) |
| Depreciation & Amortization | 1.88M | 1.6M | 929K | 936K | 569.8K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.21M | 4.24M | 3.42M | 2.58M | 5.49M |
| Change in Working Capital | (877K) | (5.63M) | 540K | 591K | (1.74M) |
| Accounts Receivables | 2M | (1.42M) | (956K) | 186K | (175.01K) |
| Inventory | (2.49M) | (1.86M) | 353K | 656K | (2.87M) |
| Accounts Payables | (356K) | (566K) | 1.35M | 815K | 384.62K |
| Other Working Capital | (26K) | (1.78M) | (211K) | (1.07M) | 918.81K |
| Other Non-Cash Items | 132K | 2.66M | 828K | 255K | (622.65K) |
| Operating Cash Flow | (22.36M) | (25.8M) | (22.61M) | (23.45M) | (38.88M) |
| Capital Expenditures | (593K) | 0 | 0 | 0 | (179.08K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (561K) | 0 | 0 | 0 | 91.63K |
| Investing Cash Flow | (593K) | 0 | 0 | 0 | (246.24K) |
| Debt Repayment | (386K) | 6.92M | (912K) | (2.56M) | (1.33M) |
| Common Stock Issued | 0 | 0 | 0 | 62.11M | 43.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.33M | 114K | 2.67M | (4.85M) | 0 |
| Financing Cash Flow | 5.95M | 7.03M | 1.76M | 54.7M | 41.86M |
| Effect of Forex Changes | 244K | (1.87M) | 549K | (2.54M) | 2M |
| Net Change in Cash | (16.76M) | (20.64M) | (20.3M) | 28.7M | 4.73M |
| Free Cash Flow | (22.95M) | (25.8M) | (22.61M) | (23.45M) | (39.05M) |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.